Alfresa Sets Terms for Japanese ASR-Linked Stock Acquisition Rights

The latest update is out from Alfresa Holdings ( (JP:2784) ).

Alfresa Holdings has set the terms for its first issuance of stock acquisition rights via a third-party allotment, tied to a fully committed share repurchase program conducted through the Tokyo Stock Exchange’s ToSTNeT-3 system. The structure allows for up to 2,208,100 exercisable shares, with the final number adjusted by the volume of shares bought at an average price derived from a VWAP-based calculation over a period starting May 19, 2026, aligning capital management with market-based pricing.

The company has earmarked a repurchase amount of approximately ¥5.25 billion, using a VWAP multiplied by 99.973% to determine the average price over the calculation period, which runs until just before the stock acquisition rights are exercised. This transaction, framed as a Japanese accelerated share repurchase, signals an ongoing effort to optimize Alfresa’s capital structure and may enhance shareholder value by reducing the share float while leveraging a transparent, formula-driven pricing mechanism.

The most recent analyst rating on (JP:2784) stock is a Hold with a Yen2400.00 price target. To see the full list of analyst forecasts on Alfresa Holdings stock, see the JP:2784 Stock Forecast page.

More about Alfresa Holdings

Alfresa Holdings is a leading player in Japan’s healthcare sector, operating across ethical and OTC pharmaceutical wholesaling, pharmaceutical manufacturing, dispensing pharmacies, regenerative medicine and CRO services. Listed on the Tokyo Stock Exchange under ticker 2784, the group reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026, underscoring its scale in the domestic market.

YTD Price Performance: -0.84%

Average Trading Volume: 360,514

Technical Sentiment Signal: Buy

Current Market Cap: Yen453.8B

Learn more about 2784 stock on TipRanks’ Stock Analysis page.